Monthly Archives: December 2012

What Key Opinion Leaders Really Want from Pharma

Increased scrutiny and new regulation have seen pharma’s relationship with key opinion leaders (KOLs) undergo a paradigm shift in recent years. Sales and marketing teams are no longer the preferred point of contact, explains Dr Samuel Dyer of the Medical Science Liaison Society. Historically, pharma companies have believed that their sales and marketing teams are […]
Posted in Guest Blog, Op-Ed | Tagged , , , | 3 Comments

Thinking of Phase IV Trials? Europe Might See Things Differently…

By Peter O’ Donnell. With the shadow cast by Mediator across Europe now receding to a focus on the French law courts, the European Union (EU) said in late November that its pharmacovigilance arrangements offer “one of the most advanced and comprehensive systems in the world”. Certainly the EU’s legislative framework has been significantly boosted […]
Posted in Europe, Global, Guest Blog, R&D | Tagged , , , , | Leave a comment
  • Categories

  • Meta